Talent Pool

Contributed by:

PharmaVOICE Staff

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Pharma pool

PV0616_BobChibBob Chib
Cassie Hogenkamp
Astellas Announces Key Leadership Appointments
Astellas has named Bob Chib and Cassie Hogenkamp to key leadership roles within its corporate development function to advance the strategic capabilities of Astellas’ Americas operations and further strengthen the company’s focus on patient needs.

Mr. Chib is serving as executive director, corporate strategy, planning and initiative management and delivery. He formerly led Astellas’ strategic accounts business unit.

Ms. Hogenkamp continues to serve as executive director, commercial strategy and innovation, where she remains focused on leading commercial strategic activities for the Americas. Previously part of the Astellas Pharma US sales and marketing organization, Ms. Hogenkamp and her team now join corporate development.

PV0616_DrAvinashDesaiDr. Avinash Desai
Paul Hawthorne
Eisai Makes Executive Appointments
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has appointed Avinash Desai, M.D., as VP, Americas oncology medical affairs for the oncology business group (OBG).

In this role, Dr. Desai leads Eisai’s oncology medical affairs team by creating and overseeing the medical strategy for the oncology commercial and market access businesses in the Americas. Dr. Desai, who has more than 20 years of experience in the oncology field,  joins Eisai from Janssen Pharmaceuticals.

Paul Hawthorne has been named senior VP, U.S. commercial, neurology business group. In this role, Mr. Hawthorne is responsible for leading the U.S. neurology sales and marketing teams in bringing Eisai’s neurology portfolio of products to patients. Mr. Hawthorne joins Eisai from Sanofi, where he spent the last 24 years; most recently, he held the position of  VP, sales.

Biotech Pool

PV0616_DrMichaelEhlersDr. Michael Ehlers
Michel Vounatsos
Biogen Strengthens Executive Team
Biogen has named Michael Ehlers, M.D., Ph.D., as executive VP, research and development. Dr. Ehlers is charged with overseeing Biogen’s global research, drug discovery, clinical development, and medical affairs functions. Dr. Ehlers joins Biogen from Pfizer, where he served as group senior VP for biotherapeutics R&D and chief scientific officer for the company’s neuroscience and pain research unit.

Michel Vounatsos has been named executive VP and chief commercial officer. Mr. Vounatsos oversees the development and execution of Biogen’s global commercial strategy.

Mr. Vounatsos comes to Biogen after a 20-year career at Merck, where he most recently served as president, primary care business line and Merck customer centricity.

PV0616_MarkEnyedyMark Enyedy
ImmunoGen Appoints President and CEO
ImmunoGen, a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, has appointed Mark Enyedy president and CEO.

Mr. Enyedy brings more than 25 years of combined general management, business development and legal experience in the biotechnology industry. He joins ImmunoGen from Shire plc, where he served as executive VP and head of corporate development, leading the company’s strategy, M&A, and corporate planning functions and providing commercial oversight for the company’s pre-Phase III portfolio.

PV0616_DrPaulResnickDr. Paul Resnick
MabVax Therapeutics Hires Chief Business Officer
MabVax Therapeutics Holdings, a clinical-stage oncology drug development company, has named Paul Resnick, M.D.,  to the newly created position of VP and chief business officer, responsible for corporate development, including engaging with large pharmaceutical and biotechnology companies on potential licensing and collaboration arrangements for its products under development.

He has more than 20 years of industry experience spanning large pharmaceutical and public and private biotechnology companies encompassing corporate development, product development, licensing and collaboration, and most recently serving as senior VP at Juventas Therapeutics.

Biopharma Pool

PV0616_DrStephenMascioliDana Alexander
Dr. Stephen Mascioli
Anika Appoints Chief Medical Officer and Chief Operations Officer
Anika Therapeutics, a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, has named Dana Alexander chief operations officer and Stephen Mascioli, M.D., to the role of chief medical officer.

Mr. Alexander brings nearly two decades of operational expertise in manufacturing and supply chain management, and he spent the last 14 years in various leadership roles at Genzyme.

Dr. Mascioli, an executive with 25 years of experience, previously held the inaugural CMO position at Terumo Americas Holdings, where he built the company’s medical department, provided strategic leadership for regulatory and clinical programs, and managed risk assessment and mitigation analysis on patient safety issues.

PV0616_DrKarinJoossDr. Karin Jooss
Gritstone Oncology Appoints Chief Scientific Officer
Gritstone Oncology, a cancer immunotherapy company developing next-generation, personalized cancer therapeutics, has named Karin Jooss, Ph.D., as chief scientific officer. Dr. Jooss joins Gritstone from Pfizer, where she served as head of cancer immunotherapeutics and immunopharmacology for seven years.

Agency Pool

PV0616_AdamGellingAdam Gelling
Giant Names President
Giant Creative/Strategy, a full-service independent healthcare communications agency , has named Principal and Chief Strategy Officer Adam Gelling, as president. He now leads the account services, strategy, client partnerships, and project management groups for Giant’s San Francisco and Philadelphia locations.(PV)

Posted in:

Post a Comment

You must be logged in to post a Comment.